Data Composite

Drug Recalls

Recent drug recall reports from the FDA (US) and Health Canada, newest first. Each entry links to the full record -- product description, reason for recall, and severity classification -- refreshed daily.

Amgen, Inc.

US Class II Ongoing · initiated 2026-06-04

Presence of Foreign Substance.

Amgen, Inc.

US Class II Ongoing · initiated 2026-06-04

Presence of Foreign Substance.

Amgen, Inc.

US Class II Ongoing · initiated 2026-06-04

CGMP Deviations

Elevate Oral Care

US Class II Ongoing · initiated 2026-06-04

sub potency

Amgen, Inc.

US Class II Ongoing · initiated 2026-06-04

CGMP Deviations

Amgen, Inc.

US Class II Ongoing · initiated 2026-06-04

CGMP Deviations

Lupin Pharmaceuticals Inc.

US Class II Ongoing · initiated 2026-06-04

Presence of Foreign Substance

Amneal Pharmaceuticals, LLC

US Class III Ongoing · initiated 2026-06-03

Cross Contamination with Other Products: due to a potential for cross-contamination with Acemetacin API due to an issue at the API manufacturer.

ChloraPrep 1 mL and 1.5 mL Applicator - Clear

Canada Type II Ongoing · initiated 2026-06-03

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…

Dabur India Limited

US Class II Ongoing · initiated 2026-06-02

CGMP Deviations; deficiencies observed during FDA inspection

Dabur India Limited

US Class II Ongoing · initiated 2026-06-02

CGMP Deviations; deficiencies observed during FDA inspection

Dabur India Limited

US Class II Ongoing · initiated 2026-06-02

CGMP Deviations; deficiencies observed during FDA inspection

Dabur India Limited

US Class II Ongoing · initiated 2026-06-02

CGMP Deviations; deficiencies observed during FDA inspection

Dabur India Limited

US Class II Ongoing · initiated 2026-06-02

CGMP Deviations; deficiencies observed during FDA inspection

Dabur India Limited

US Class II Ongoing · initiated 2026-06-02

CGMP Deviations; deficiencies observed during FDA inspection

Dabur India Limited

US Class II Ongoing · initiated 2026-06-02

CGMP Deviations; deficiencies observed during FDA inspection

Dabur India Limited

US Class II Ongoing · initiated 2026-06-02

CGMP Deviations; deficiencies observed during FDA inspection

Dabur India Limited

US Class II Ongoing · initiated 2026-06-02

CGMP Deviations; deficiencies observed during FDA inspection

Dabur India Limited

US Class II Ongoing · initiated 2026-06-02

CGMP Deviations; deficiencies observed during FDA inspection

Dabur India Limited

US Class II Ongoing · initiated 2026-06-02

CGMP Deviations; deficiencies observed during FDA inspection

Dabur India Limited

US Class II Ongoing · initiated 2026-06-02

CGMP Deviations; deficiencies observed during FDA inspection

Dabur India Limited

US Class II Ongoing · initiated 2026-06-02

CGMP Deviations; deficiencies observed during FDA inspection

Dabur India Limited

US Class II Ongoing · initiated 2026-06-02

CGMP Deviations; deficiencies observed during FDA inspection

Central Admixture Pharmacy Services, Inc.

US Class II Ongoing · initiated 2026-06-02

Incorrect product formulation: bag did not contain copper and famotidine per label.

ANI Pharmaceuticals, Inc.

US Class III Ongoing · initiated 2026-06-02

Presence of foreign substance